Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose) - Parmar, Deven V.; Kansagra, Kevinkumar A.; Momin, Taufik; Patel, Hardik B.; Jansari, Gaurav A.; Bhavsar, Jay; Shah, Chintan; Patel, Jayesh M.; Ghoghari, Ashok; Barot, Ajay; Sharma, Bhavesh; Viswanathan, Kasinath; et al. (Clinical pharmacology in drug development, 2023)
Keywords: Area Under Curve; Drug dosages; healthy subjects; Humans; Inflammasomes - metabolism; Inhibitor drugs; Interleukin-18 - metabolism; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; NLRP3 inflammasome inhibitor; Original; pharmacodynamic; Pharmacodynamics; pharmacokinetic; Pharmacokinetics; safety; ZYIL1; ZYIL1; pharmacodynamic; pharmacokinetic; healthy subjects; safety; NLRP3 inflammasome inhibitor